Therapeutics targeting IL-13 for the treatment of pulmonary inflammation and airway remodeling.
Curr Opin Investig Drugs
; 9(11): 1180-4, 2008 Nov.
Article
em En
| MEDLINE
| ID: mdl-18951297
ABSTRACT
Targeting the IL-13 pathway appears to be a viable approach to ameliorate pulmonary inflammation and remodeling. Support for this hypothesis comes from preclinical and preliminary clinical data. Diverse approaches have been used to target the IL-13 pathway, including neutralizing antibodies specific for IL-13, targeting IL-13 receptors using antibodies or chimeric proteins, and therapeutics that target the downstream signaling molecules that are activated upon binding of the IL-13 receptor to its ligand. This review summarizes the progress made in the development of therapeutics targeting the IL-13 pathway for treating diseases associated with inflammation and remodeling of the lung.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Fibrose Pulmonar
/
Asma
/
Hiper-Reatividade Brônquica
/
Interleucina-13
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Curr Opin Investig Drugs
Assunto da revista:
TERAPIA POR MEDICAMENTOS
Ano de publicação:
2008
Tipo de documento:
Article
País de afiliação:
Estados Unidos